Latest News

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer proffered paper session included a presentation by Dr. Alexandros Papachristofilou discussing results from the SAKK 01/10 phase II trial testing a single dose of carboplatin followed by involved-node radiotherapy as curative treatment for seminoma stage IIA/B. Seminoma stage IIA/IIB is defined as […]

(UroToday.com) In this presentation, Dr. Gerhardt Attard discussed results of abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer. This study comprised a combined analysis from two comparisons in the STAMPEDE platform.

(UroToday.com) In this presentation, Dr. Toni Choueiri discussed patient reported outcomes (PROs) from KEYNOTE-564, a randomized phase 3 study of adjuvant Pembrolizumab versus placebo in patients with renal cell carcinoma (RCC). Results of the KEYNOTE-564 trial, initially presented at the ASCO 2021 Annual Meeting and recently published in the New England Journal of Medicine, demonstrated an […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 virtual annual meeting’s non-prostate cancer proffered paper session included a presentation by Dr. Naveen Vasudev discussing results of the phase II PRISM trial assessing nivolumab combination with alternatively scheduled ipilimumab in first-line treatment of advanced renal cell carcinoma (RCC). Ipilimumab plus nivolumab is a standard first-line […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer session included a presentation by Dr. Rustem Gafanov discussing results of subsequent therapy in KEYNOTE-426 for patients treated with pembrolizumab + axitinib or sunitinib for advanced RCC. First-line combination treatment of an anti-PD-1/PD-L1 with a VEGFR inhibitor is considered standard of care […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer session included a presentation by Dr. Camillo Porta discussing subgroup analyses of the CheckMate 9ER trial assessing first-line nivolumab + cabozantinib versus sunitinib among patients with advanced RCC. Previously, first-line nivolumab + cabozantinib showed a significantly improved progression-free survival (PFS), overall survival […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer session included a presentation by Dr. Jae-Lyun Lee discussing updated data of pembrolizumab monotherapy among patients with non-clear cell renal cell carcinoma (RCC) from Cohort B of the KEYNOTE-427 trial. Approved therapies for non-clear cell RCC are needed because most clinical trials […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer session included a presentation by Dr. Camillo Porta discussing results of a comparison of health-related quality of life of nivolumab plus cabozantinib versus pembrolizumab plus axitinib in previously untreated advanced RCC. The landscape for first-line advanced RCC is rapidly evolving, with pembrolizumab plus […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer session included a presentation by Dr. David McDermott discussing long-term outcomes in the KEYNOTE-427 Cohort A trial of pembrolizumab monotherapy for first-line treatment of advanced renal cell carcinoma (RCC). A number of combination therapies involving immune checkpoint inhibitors, including the PD-1 inhibitor pembrolizumab, […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer session included a presentation by Dr. Marc-Oliver Grimm discussing the role of prior nephrectomy on outcomes of avelumab + axitinib versus sunitinib in the JAVELIN Renal 101 trial for metastatic renal cell carcinoma (RCC). Cytoreductive nephrectomy has been a standard of care in […]